Over the past quarter-century, the number of people worldwide living with Parkinson’s disease has doubled, yet methods of treatment and monitoring remain outdated. Clinicians still rely on subjective rating scales to assess symptoms, and many patients wait months or even years between visits to a trained neurologist. This gap leaves patients uncertain about how their condition is progressing or whether their medication regimes are working effectively. The shortage of movement disorder specialists, who comprise only a small fraction of physicians, exacerbates the challenge and hampers the development of new therapies.
Researchers at Stanford Medicine have sought to address this unmet need with a simple, portable device known as the KeyDuo, paired with a digital platform called Quantitative DigitoGraphy Care. This system enables patients to monitor their Parkinson’s symptoms from home using just two tactile levers connected to a smartphone or tablet. The device translates subtle details of finger tapping—such as pressure, speed and amplitude—into quantifiable data that can be transmitted directly to clinicians. In turn, physicians gain real-time insights into their patients’ motor performance without relying solely on occasional in-person assessments.
The idea originated from earlier work on a computerised keyboard designed for musicians with dystonia. When a pianist with Parkinson’s tested the keyboard both on and off medication, researchers noticed the difference in the resulting data. Refinements led to the KeyDuo, engineered to measure not only taps but also joint rigidity, something previously impossible to capture outside an in-person examination. Patients complete a short test by alternating finger taps for thirty seconds, and the device instantly generates a detailed motor assessment for physicians to review.
Clinical studies have underscored the device’s promise. In one trial, patients used the whole system at home for 30 days, testing themselves twice daily. The results provided valuable information on symptom fluctuations in response to medication, offering a day-to-day picture of disease progression. Another study demonstrated the system’s ability to detect tremors with 98% sensitivity, a breakthrough in capturing a symptom that often eludes even trained examiners during clinic visits. Compliance rates were high, showing that patients found the technology both practical and easy to use.
The benefits of such objective monitoring are far-reaching. For clinicians, it provides consistent, validated data that reduces reliance on subjective scales. For patients, it fosters more frequent connections with providers between visits, enabling them to manage their medication schedules better. The device could also support primary care physicians who lack specialist training, providing them with reliable data to inform treatment decisions. Researchers also stand to gain, as continuous, high-resolution monitoring could streamline clinical trials and accelerate the testing of new therapies.
Ultimately, the Stanford team envisions their technology transforming Parkinson’s care in much the same way continuous glucose monitoring has revolutionised diabetes management. By shifting evaluation from sporadic clinic visits to continuous, real-world data collection, the KeyDuo and its digital platform promise to improve both day-to-day care and long-term outcomes for patients living with Parkinson’s disease.
More information: Helen Bronte-Stewart et al, Remote real time digital monitoring fills a critical gap in the management of Parkinson’s disease, Nature. DOI: 10.1038/s41531-025-01101-0
Journal information: Nature Provided by Stanford Medicine
